<br>        Inclusion Criteria:<br><br>          1. Written informed consent consistent with ICH-GCP and local IRB/IEC requirements<br>             obtained prior to any study procedures being performed and the ability and<br>             willingness to comply with study treatment regimen and to attend study assessments.<br><br>          2. Male or female out-patients aged 18-80 years.<br><br>          3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG<br>                          [P03-03355]. All four criteria must be present to fulfil the diagnosis<br>             of RLS:<br><br>             An urge to move the legs, usually accompanied or caused by uncomfortable and<br>             unpleasant sensations in the legs. (Sometimes the urge to move is present without the<br>             uncomfortable sensations and sometimes the arms or other body parts are involved in<br>             addition to the legs) The urge to move or unpleasant sensations begin or worsen<br>             during periods of rest or inactivity such as lying or sitting The urge to move or<br>             unpleasant sensations are partially or totally relieved by movement, such as walking<br>             or stretching, at least as long as the activity continues The urge to move or<br>             unpleasant sensations are worse in the evening or night than during the day or only<br>             occur in the evening or night. (When symptoms are very severe, the worsening at night<br>             may not be noticeable but must have been previously present).<br><br>          4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to<br>             baseline (Visit 2).<br><br>          5. In addition all of the following must be demonstrated at Visit 2 (baseline):<br><br>        IRLS total score >15 A score of >=2 for item 10 of the IRLS rating scale<br><br>        Exclusion Criteria:<br><br>          1. Women of child-bearing potential who do not use an adequate method of contraception<br><br>          2. Any women of child-bearing potential not having negative pregnancy test at screening<br><br>          3. Breastfeeding women<br><br>          4. Concomitant or previous pharmacologic therapy for RLS<br><br>          5. All treatment less than 14 days before baseline or concomitant treatment with<br>             medication or dietary supplements, which could significantly influence RLS symptoms<br><br>          6. Withdrawal symptoms of any medication must not be present at baseline<br><br>          7. Previous pramipexole non-responders in other indications than RLS.<br><br>          8. Hypersensitivity to pramipexole or any other component of the investigational product<br><br>          9. Diagnosis of diabetes mellitus requiring insulin<br><br>         10. Any of the following laboratory results at screening: clinically significant<br>             abnormalities at the investigatos discretion; Hb below lower limit of normal<br><br>         11. Clinically significant renal disease at screening<br><br>         12. Clinically significant hepatic disease at screening<br><br>         13. Serum ferritin <10 ng/mL at screening.<br><br>         14. History of/or malignant melanoma.<br><br>         15. History of/or clinically significant vision abnormalities<br><br>         16. History of/or any other sleep disorder<br><br>         17. History of/or major depressive disorder or any psychotic disorder, mental disorders<br>             or any present Axis I psychiatric disorder according to DSM IV requiring any medical<br>             therapy, or BDI-II total score >28<br><br>         18. History of/or clinical signs of suicidal behaviour, suicide ideation or acute<br>             suicidal tendency according to the investigators opinion<br><br>         19. History of/or alcohol abuse or drug addiction within the last 2 years before<br>             screening<br><br>         20. Patients on a shift-work-schedule or otherwise unable to follow a regular sleep-wake<br>             cycle<br><br>         21. Participation in an investigational drug study within one month prior to the start of<br>             this study<br><br>         22. Patients with any clinically significant conditions that in the opinion of the<br>             investigator<br>